National Cancer Institute; Notice of Meeting, 66034 [2013-26253]
Download as PDF
<![CDATA[
66034
Federal Register / Vol. 78, No. 213 / Monday, November 4, 2013 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
TKELLEY on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public as indicated below
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance and the
competence of individual investigators.
Additionally for the review of grant
applications and the discussions, that
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board; Ad hoc Subcommittee on
Global Cancer Research.
Open: December 9, 2013, 6:00 p.m. to 7:30
p.m.
Agenda: Discussion on Global Cancer
Research.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, Maryland
20814.
Contact Person: Dr. Edward Trimble,
Executive Secretary, NCAB Ad hoc
Subcommittee on Global Cancer Research,
National Cancer Institute, National Institutes
of Health, 9609 Medical Center Drive, Room
3W–562, Bethesda, MD 20892, (240) 276–
5796, trimblet@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board; Ad hoc Subcommittee on
Communications.
Open: December 9, 2013, 7:45 p.m. to 9:15
p.m.
Agenda: Discussion on Communications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, Maryland
20814.
Contact Person: Dr. Lenora Johnson,
Executive Secretary, NCAB Ad hoc
VerDate Mar<15>2010
17:07 Nov 01, 2013
Jkt 232001
Subcommittee on Communications, National
Cancer Institute, National Institutes of
Health, 9606 Medical Center Drive, Room
2E–454, Bethesda, MD 20892, (240) 276–
6680, johnslen@mail.nih.gov.
Name of Committee: National Cancer
Advisory Board.
Open: December 10, 2013, 9:00 a.m. to 3:30
p.m.
Agenda: Program reports and
presentations; business of the Board.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Name of Committee: National Cancer
Advisory Board.
Closed: December 10, 2013, 3:30 p.m. to
5:00 p.m.
Agenda: Review intramural program site
visit outcomes. Discussion of confidential
and personnel issues. Review and evaluate
grant applications.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W–444,
Bethesda, MD 20892, (240) 276–6340.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: NCAB:
deainfo.nci.nih.gov/advisory/ncab.htm where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS).
Dated: October 29, 2013.
Melanie Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–26253 Filed 11–1–13; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing For
Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
laboratories and IITF is published in the
Federal Register during the first week of
each month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
SUMMARY:
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 78, Number 213 (Monday, November 4, 2013)]
[Notices]
[Page 66034]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-26253]
[[Page 66034]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of meeting of the
National Cancer Advisory Board.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
A portion of the meeting will be closed to the public as indicated
below in accordance with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review,
discussion, and evaluation of individual intramural programs and
projects conducted by the National Cancer Institute, including
consideration of personnel qualifications and performance and the
competence of individual investigators. Additionally for the review of
grant applications and the discussions, that could disclose
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Advisory Board; Ad hoc
Subcommittee on Global Cancer Research.
Open: December 9, 2013, 6:00 p.m. to 7:30 p.m.
Agenda: Discussion on Global Cancer Research.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center,
Bethesda, Maryland 20814.
Contact Person: Dr. Edward Trimble, Executive Secretary, NCAB Ad
hoc Subcommittee on Global Cancer Research, National Cancer
Institute, National Institutes of Health, 9609 Medical Center Drive,
Room 3W-562, Bethesda, MD 20892, (240) 276-5796,
trimblet@mail.nih.gov.
Name of Committee: National Cancer Advisory Board; Ad hoc
Subcommittee on Communications.
Open: December 9, 2013, 7:45 p.m. to 9:15 p.m.
Agenda: Discussion on Communications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center,
Bethesda, Maryland 20814.
Contact Person: Dr. Lenora Johnson, Executive Secretary, NCAB Ad
hoc Subcommittee on Communications, National Cancer Institute,
National Institutes of Health, 9606 Medical Center Drive, Room 2E-
454, Bethesda, MD 20892, (240) 276-6680, johnslen@mail.nih.gov.
Name of Committee: National Cancer Advisory Board.
Open: December 10, 2013, 9:00 a.m. to 3:30 p.m.
Agenda: Program reports and presentations; business of the
Board.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray, Executive Secretary,
National Cancer Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W-444, Bethesda, MD 20892, (240) 276-
6340.
Name of Committee: National Cancer Advisory Board.
Closed: December 10, 2013, 3:30 p.m. to 5:00 p.m.
Agenda: Review intramural program site visit outcomes.
Discussion of confidential and personnel issues. Review and evaluate
grant applications.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray, Executive Secretary,
National Cancer Institute, National Institutes of Health, 9606
Medical Center Drive, Room 7W-444, Bethesda, MD 20892, (240) 276-
6340.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: NCAB: deainfo.nci.nih.gov/advisory/ncab.htm where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS).
Dated: October 29, 2013.
Melanie Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-26253 Filed 11-1-13; 8:45 am]
BILLING CODE 4140-01-P
